Klin Farmakol Farm. 2007;21(2):87-89

Hodnocení klinického a ekonomického prospěchu léčby nadváhy sibutraminem (Meridií) ve všeobecné lékařské praxi

Petr Petr1,3,2,4
1 Pracoviště klinické farmakologie, Nemocnice České Budějovice, a.s
2 EMA - European Medical Agency, n. ,f., České Budějovice
3 Vysoká škola technická a ekonomická, České Budějovice
4 Zdravotně sociální fakulta Jihočeské univerzity, Katedra veřejného a sociálního zdravotnictví, České Budějovice

V říjnu 2006 publikovali Alan Brennan a Robert Ara z Velké Británie, spolu s Raimundem Sterzem, Berndtem Matibou a Rito Bergman­nem z Německa, souhrnnou práci metaanalytického charakteru, ve které shrnují současný stav znalostí o klinickém a ekonomickém prospěchu, který přináší léčba obezity/nadváhy sibutraminem (Meridia, Reductil).

Published: October 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petr P. Hodnocení klinického a ekonomického prospěchu léčby nadváhy sibutraminem (Meridií) ve všeobecné lékařské praxi. Klin Farmakol Farm. 2007;21(2):87-89.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anonymous. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;8941: 253.
    2. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83: 356-362. Go to original source... Go to PubMed...
    3. Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8(21): 111-182. Go to original source... Go to PubMed...
    4. Bergmann KE, Mensink GB. Anthropometric data and obesity (in German). Gesundheitswesen 1999;61: 115-120.
    5. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13: 873-884. Go to original source... Go to PubMed...
    6. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51: 1115-1128. Go to original source... Go to PubMed...
    7. Bundesministerium für Gesundheit und Soziale Sicherung und Bundesministerium für Bildung und Forschung. Body-Mass-Index - Prävalenzen. Bundes-Gesundheitssurvey 1998. Statistisches Bundesamt und Robert Koch-Institut. 2003. Electronic Citation.
    8. Büro für Informations Systeme (BIS) Christian de Haen (2004) Einheitlicher Bewertungsmassstab (EBM98). http://www.e-bis.de/ebm/Default.htm.
    9. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 2003;348: 1625-1638. Go to original source... Go to PubMed...
    10. Doležal T. Farmakoekonomika ve světě a v České republice. Pharm Business Magazine 2007;3(2): 24-26.
    11. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289: 1799-1804. Go to original source... Go to PubMed...
    12. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288: 1723-1727. Go to original source... Go to PubMed...
    13. Fontaine KR, Cheskin LJ, Barofsky I. Health-related quality of life in obese persons seeking treatment. J Fam Pract 1996;43: 265-270.
    14. Fontaine KR, Redden DT, Wang C et al. Years of life lost due to obesity. JAMA 2003, 289: 187-193. Go to original source... Go to PubMed...
    15. Hauner H, Meier M, Wendland G, Lauterbach K. Weight reduction by sibutramine in obese subjects in primary care medicine: the S. A. T. study group. Exp Clin Endocrinol Diabetes 2004;112: 201-207. Go to original source... Go to PubMed...
    16. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000;94: 152-158. Go to original source... Go to PubMed...
    17. Heitmann BL, Garby L. Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 years. Int J Obes Relat Metab Disord 1999;23: 1074-1078. Go to original source... Go to PubMed...
    18. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67: 968-977. Go to original source... Go to PubMed...
    19. James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356: 2119-2125. Go to original source... Go to PubMed...
    20. Jönsson B. Revealing the cost of Ttpe II diabetes in Europe. Diabetologia 2002;45(7): S5-12. Go to original source...
    21. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002;347: 305-313. Go to original source... Go to PubMed...
    22. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316: 736-741. Go to original source... Go to PubMed...
    23. Klever-Deichert G, Hinzpeter B, Hunsche E, Lauterbach KW. Costs of coronary heart diseases over the remaining life time in coronary heart disease cases - an analysis of the current status of coronary heart disease cases in Germany from the social perspective (in German). Z Kardiol 1999;88: 991-1000. Go to original source... Go to PubMed...
    24. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393-403. Go to original source... Go to PubMed...
    25. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94: 957-965. Go to original source... Go to PubMed...
    26. Kurscheid T, Lauterbach K. The cost implications of obesity for health care and society. Int J Obes Relat Metab Disord 1998;22(Suppl 1): S3-5.
    27. Narayan KM, Boyle JP, Thompson TJ et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290: 1884-1890. Go to original source... Go to PubMed...
    28. Neter JE, Stam BE, Kok FJ et al. Influence of weight reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension 2003;42: 878-884. Go to original source... Go to PubMed...
    29. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003;26: 1027-1048. Go to original source... Go to PubMed...
    30. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002, 288: 1728-1732. Go to original source... Go to PubMed...
    31. Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women s Health Study. Int J Obes Relat Metab Disord 2003;27: 1447-1452.
    32. Peeters A, Barendregt JJ, Willekens F et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138: 24-32. Go to original source... Go to PubMed...
    33. Pickin DM, McCabe CJ, Ramsay LE et al. Cost effectiveness of HMG-CoA reductase inhibito (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82: 325-332. Go to original source... Go to PubMed...
    34. Rexrode KM, Carey VJ, Hennekens CH et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998, 280: 1843-1848. Go to original source... Go to PubMed...
    35. Rote Liste Service (2004) Rote Liste, Arzneimittelverzeichnis für Deutschland. http://www.rote-liste.de.
    36. Sander B, Bergemann R. Economic burden of obesity and its complications in Germany. Eur J Health Econ 2003;4: 248-253. Go to original source... Go to PubMed...
    37. Scholze J. Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters (in German). Dtsch Med Wochenschr 2002;127: 606-610. Go to original source... Go to PubMed...
    38. Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA 2003, 289: 1813-1819. Go to PubMed...
    39. Seidell JC. Obesity, insulin resistance and diabetes - a worldwide epidemic. Br J Nutr 2000;83(Suppl 1): S5-8. Go to original source... Go to PubMed...
    40. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50: 505-512. Go to original source...
    41. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344: 1343-1350. Go to original source... Go to PubMed...
    42. Vasan RS. Cardiac function and obesity. Heart 2003;89: 1127-1129. Go to original source... Go to PubMed...
    43. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004;24: 9-19. Go to original source... Go to PubMed...
    44. Williamson DF, Thompson TJ, Thun M et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23: 1499-1504. Go to original source... Go to PubMed...
    45. Winkelmayer WC, Weinstein MC, Mittleman MA et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;22: 417-430. Go to original source... Go to PubMed...
    46. Wirth A. Anhaltende Gewichtsreduktion nach Beendigung der Adipositasbehandlung mit Sibutramin. Dtsch Med Wochenschr 2004;129: 1002-1005. Go to original source... Go to PubMed...
    47. Wirth A, Krause J Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001, 286: 1331-1339. Go to original source... Go to PubMed...
    48. Zannad F, Gille B, Grentzinger A et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144: 508-515. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.